Pfizer Elaborates On Celebrex Safety Theory: Molecule Is “Unique”

Celebrex can be differentiated from other COX-2 inhibitors based on relative rates of association with hypertensive cell retention, Pfizer Worldwide Development President Joe Feczko told analysts Nov. 30 in Groton, Conn